Catalyst Pharmaceuticals
Tracked across 3 events · 18 articles · First seen Apr 23, 2026 · Last active Jul 01, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Catalyst Pharmaceuticals conducted the Phase 1 study of AGAMREE and holds commercialization rights in North America. Positive results support its potential to expand the drug's use beyond Duchenne muscular dystrophy, increasing its market potential.
Jul 01, 2026 · 6 articles
Business
Impact: Santhera Pharmaceuticals has partnered with Catalyst Pharmaceuticals for the North American rights to AGAMREE.
Apr 23, 2026 · 6 articles
Business
Impact: Catalyst Pharmaceuticals holds the North American rights to AGAMREE, licensed from Santhera Pharmaceuticals.
Apr 30, 2026 · 6 articles
90
Catalyst Pharmaceuticals conducted clinical studyAGAMREE Phase 1 Study Results
ERGEN INTELLIGENCE
Track Catalyst Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard